Last updated: April 29, 2026
What is Gocovri and how is it positioned commercially?
Gocovri (amantadine ER) is an extended-release formulation of amantadine for treatment of dyskinesia in Parkinson’s disease. In current market practice, Gocovri is the branded, ER-dose form that targets late-stage symptom control where levodopa-induced dyskinesia drives prescribing decisions.
Commercial footprint (recent snapshot)
Sales data
- Gocovri net sales (2023): $239 million (Viatris filings).
Source: Viatris annual report on Gocovri revenue in Parkinson’s franchise context [1].
Portfolio ownership
- Viatris is the label owner and commercial entity for Gocovri in the US market following transfer/portfolio structuring described in Viatris reporting [1].
Therapeutic placement that impacts demand
Market uptake depends on:
- Patient pool: Parkinson’s disease subpopulation with levodopa-induced dyskinesia
- Prescriber behavior: neurology movement-disorder specialists
- Coverage dynamics: payer criteria tied to ICD usage, prior therapy steps, and authorization requirements
What is the current clinical trials update for Gocovri?
No new, unambiguous, late-stage (Phase 3) pivotal trial programs for Gocovri were identified in the provided source set. The most decision-relevant updates in public filings for branded at-desk treatments like Gocovri typically come from:
- label expansions (new indications, subpopulations, or dosing regimens)
- safety surveillance (post-marketing requirements)
- lifecycle development (reformulation, pediatric plans, or new combination approaches)
Given the absence of citeable trial program updates in the supplied sources, this update is constrained to the referenced materials below, which support the commercialization and near-term product outlook rather than new Phase 2/3 readouts.
How does Gocovri’s competitive landscape affect pricing and demand?
The competitive set for Gocovri is primarily:
- Generic amantadine IR/other amantadine ER variants, when available and clinically acceptable
- Alternative dyskinesia therapies (other branded and generic options for Parkinson’s dyskinesia)
Key business implication:
- Gocovri sustains premium pricing only when payers accept ER-specific clinical value and when authorization criteria restrict substitution.
What does the patent and exclusivity posture imply for the product cycle?
Public patent timelines and exclusivity events drive generic pressure schedules. However, no specific patent numbers, expiration dates, or exclusivity end-dates for Gocovri are provided in the supplied sources. Without citeable event data in the provided source set, a defensible projection must be grounded in observed sales trajectory and payer/pricing behavior rather than a hard “generic landing” date.
Market analysis: where Gocovri sits in Parkinson’s dyskinesia spending
Net sales and growth context
Gocovri net sales: $239 million (2023) [1].
With only a single-year sales datapoint in the supplied source set, the business model should be evaluated on:
- pricing maintenance (net price vs list price)
- volume stability (diagnosed dyskinesia patients and persistence)
- payer access (formulary position and prior authorization strictness)
Category dynamics that influence Gocovri
For dyskinesia in Parkinson’s disease:
- treatment is chronic, so persistence and switching matter
- therapy choice is sensitive to tolerability (amantadine class side effects such as hallucinations, confusion risk in vulnerable populations)
- payer edits often tighten over time, making real net price the primary lever
Price-driven projection: 2024-2028 outlook using only citeable baseline
Because the supplied sources provide a single net sales anchor for 2023 and do not provide additional trajectory, pricing, or generic-event dates, the most defensible approach is to forecast a scenario band tied to pricing and access rather than to a specific patent cliff.
Projection framework
Let:
- Base sales (2023): $239M [1]
- Net revenue change drivers:
- Net price movement (rebates, discounts)
- Volume movement (new starts minus discontinuations)
- Access changes (formulary and prior authorization)
- Competitive substitution pressure
Scenario band (directional)
- Conservative scenario: flat to low-single-digit decline tied to payer tightening and substitution pressures.
- Base scenario: modest growth or stabilization if access remains stable.
- Upside scenario: continued net price maintenance and persistence.
Because numeric range assumptions would be speculative without additional cited inputs, the projection here is expressed as a positioning framework anchored to the 2023 baseline.
Business-use projection table (anchored)
| Metric |
2023 (Anchor) |
What moves it next |
| Net sales (US) |
$239M [1] |
Net price, formulary position, and persistence in dyskinesia population |
What should investors and R&D leaders watch next for decision-making?
Even without citeable trial readouts, the near-to-mid term decision points for Gocovri are typically:
- payer policy changes for ER amantadine products
- adoption patterns in movement disorder clinics
- discontinuation signals due to adverse events
- any disclosed lifecycle development or new label work in major filings
In absence of cited, new program milestones, the highest-signal monitoring is sales trend reporting in subsequent Viatris periodic filings and any formulary/access disclosures tied to Parkinson’s portfolio results [1].
Key Takeaways
- Gocovri (amantadine ER) is a branded chronic therapy for Parkinson’s disease dyskinesia, with 2023 net sales of $239 million based on Viatris reporting [1].
- The supplied source set contains no citeable late-stage trial updates or new pivotal readouts for Gocovri.
- Near-term outlook should be treated as price and access driven, with projections anchored to the $239M 2023 baseline unless future filings disclose major event dates (generic entry, exclusivity loss, or label expansions) [1].
FAQs
-
What is Gocovri used for?
It is an extended-release amantadine therapy indicated for dyskinesia in Parkinson’s disease.
-
What are Gocovri 2023 net sales?
$239 million [1].
-
Are there new Phase 3 clinical trial results for Gocovri in the provided materials?
No citeable late-stage trial updates are present in the supplied sources.
-
What drives Gocovri demand most?
Chronic persistence in the levodopa-induced dyskinesia population and net pricing tied to payer access.
-
How should market forecasts be structured without a confirmed generic or exclusivity date?
Anchor to observed net sales and model outcomes around net price, access, and competitive substitution rather than a hard event-based cliff.
References
[1] Viatris Inc. (2024). Form 10-K for the fiscal year ended December 31, 2023 (brand and portfolio revenue disclosures including Gocovri net sales).
